TuHURA Biosciences Q3 R&D expenses fall 26% to $3.7 million
HURA•TuHURA Biosciences reported third-quarter 2026 research and development expenses of $3.7 million, down 26% year over year, and cash and cash equivalents of $1.9 million at September 30. The FDA cleared a Phase 1b trial of TBS-2025 in patients with relapsed or refractory mutNPM1 acute myeloid leukemia after menin inhibitor treatment failure.
1. Quarterly expenses
Third-quarter research and development expenses fell 26% year over year to $3.7 million, primarily due to lower manufacturing costs. General and administrative expenses rose 25% to $2 million, mainly because of higher noncash stock compensation and public-company costs.
2. Cash and trial clearance
Operating cash outflows narrowed 18% year over year to $18.1 million for the nine months ended September 30, 2026. TuHURA had $1.9 million in cash and cash equivalents at September 30, and the Parkview loan facility provided $5.6 million during the third quarter. FDA clearance allows a Phase 1b trial of TBS-2025 in relapsed or refractory mutNPM1 acute myeloid leukemia following menin inhibitor treatment failure.
